
16.2 SUBJECT DATA LISTINGS

16.2 SUBJECT DATA LISTINGS.....	1
16.2.1 Discontinued Subjects	2
16.2.2 Protocol Deviations	11
16.2.3 Subjects Excluded From the Efficacy Analysis	14
16.2.4 Demographic Data and Other Baseline Characteristics	16
16.2.5 Compliance and/or Drug Concentration Data	20
16.2.6 Pharmacokinetic, extraction and response data.....	56
16.2.7 Adverse Event Listings.....	168
16.2.8 Listing of Individual Laboratory Measurements by Subject	171


16.2.1 Discontinued Subjects

Listing 16.2.1-1 Discontinued subjects.....	3
Listing 16.2.1-2 Disposition (all subjects)	3
Listing 16.2.1- 3 Screening failures.....	6
Listing 16.2.1-4 Subject visits (all subjects)	6

Listing 16.2.1-1

Discontinued subjects


(b) (4)

A large black rectangular redaction box covering the entire table content for Listing 16.2.1-1. The text "(b) (4)" is written in red at the top left corner of the redacted area.

Listing 16.2.1-2

Disposition (all subjects)

(b) (4)

A large black rectangular redaction box covering the entire table content for Listing 16.2.1-2. The text "(b) (4)" is written in red at the top left corner of the redacted area.

(b) (4)



(b) (4)



Listing 16.2.1- 3

Screening failures

(b) (4)



Listing 16.2.1-4

Subject visits (all subjects)

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)




16.2.2 Protocol Deviations

Listing 16.2.2- 1 Protocol deviations	12
---	----

Listing 16.2.2- 1

Protocol deviations

(b) (4)



(b) (4)



16.2.3 Subjects Excluded From the Efficacy Analysis

Listing 16.2.3- 1 Subjects excluded from the per protocol set.....	15
--	----

Listing 16.2.3- 1

Subjects excluded from the per protocol set

(b) (4)



16.2.4 Demographic Data and Other Baseline Characteristics

Listing 16.2.4- 1 Demographics	17
Listing 16.2.4- 2 Medical history (all subjects).....	18
Listing 16.2.4- 3 Prior and concomitant medications (part 1, indications, all subjects).....	18
Listing 16.2.4- 4 Prior and concomitant medications (part 2, durations, all subjects)	19

Listing 16.2.4- 1

Demographics


(b) (4)



Listing 16.2.4- 2

Medical history (all subjects)


(b) (4)



Listing 16.2.4- 3

Prior and concomitant medications (part 1, indications, all subjects)

(b) (4)



Listing 16.2.4- 4

Prior and concomitant medications (part 2, durations, all subjects)

(b) (4)




16.2.5 Compliance and/or Drug Concentration Data

Listing 16.2.5- 1 Plasma levels – nicotine (all subjects).....	21
--	----

Listing 16.2.5- 1

Plasma levels – nicotine (all subjects)

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



16.2.6 Pharmacokinetic, extraction and response data

Listing 16.2.6- 1	Estimated exposure to study product, nicotine extraction (all subjects)	57
Listing 16.2.6- 2	Pharmacokinetic parameters – nicotine (non-baseline adjusted original calculations used in the CSR, per protocol set)	61
Listing 16.2.6- 3	Pharmacokinetic parameters – nicotine (non-baseline adjusted data, per protocol set)	82
Listing 16.2.6- 4	Pharmacokinetic parameters – nicotine (baseline adjusted data, per protocol set)	103
Listing 16.2.6- 5	Individual efficacy response data – pulse.....	124
Listing 16.2.6- 6	Individual efficacy response data – VAS	146

Listing 16.2.6- 1

Estimated exposure to study product, nicotine extraction (all subjects)

(b) (4)



(b) (4)



(b) (4)



(b) (4)



Listing 16.2.6- 2

Pharmacokinetic parameters – nicotine (non-baseline adjusted original calculations used in the CSR, per protocol set)

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)




(b) (4)



Listing 16.2.6- 3

Pharmacokinetic parameters – nicotine (non-baseline adjusted data, per protocol set)

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)




(b) (4)



Listing 16.2.6- 4

Pharmacokinetic parameters – nicotine (baseline adjusted data, per protocol set)

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



Listing 16.2.6- 5

Individual efficacy response data – pulse

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



Listing 16.2.6- 6

Individual efficacy response data – VAS

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



16.2.7 Adverse Event Listings

Listing 16.2.7- 1 Adverse events (part 1, duration in relation to study treatment, all subjects)	169
Listing 16.2.7- 2 Adverse events (part 2, coding and severity, all subjects)	170

Listing 16.2.7- 1

Adverse events (part 1, duration in relation to study treatment, all subjects)


(b) (4)



Listing 16.2.7- 2

Adverse events (part 2, coding and severity, all subjects)

(b) (4)



16.2.8 Listing of Individual Laboratory Measurements by Subject

Listing 16.2.8- 1 Laboratory tests (drug screening, HIV, Hepatitis B and C)172

Listing 16.2.8- 1

Laboratory tests (drug screening, HIV, Hepatitis B and C)

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)

